Influence of adrenergic blockers and antilipemic agents on pharmacodynamic actions of morphine in carbon tetrachloride-treated rats.
D000818:Animals; D002251:Carbon Tetrachloride / Q000494:pharmacology*; D003983:Dibenzylchlorethamine / Q000494:pharmacology; D004357:Drug Synergism; D004878:Ergotamine / Q000494:pharmacology; D005260:Female; D006439:Hemodynamics / Q000187:drug effects; D006493:Heparin / Q000494:pharmacology; D000960:Hypolipidemic Agents / Q000494:pharmacology*; D050356:Lipid Metabolism; D008099:Liver / Q000033:anatomy & histology / Q000378:metabolism; D008297:Male; D009020:Morphine / Q000037:antagonists & inhibitors* / Q000494:pharmacology / Q000652:urine; D009539:Nicotinic Acids / Q000494:pharmacology; D011433:Propranolol / Q000494:pharmacology; D051381:Rats; D011930:Reaction Time / Q000187:drug effects; D013565:Sympatholytics / Q000494:pharmacology*; D014043:Tolazoline / Q000494:pharmacology
D000960:Hypolipidemic Agents; D009539:Nicotinic Acids; D013565:Sympatholytics; D003983:Dibenzylchlorethamine; D009020:Morphine; D006493:Heparin; D011433:Propranolol; D014043:Tolazoline; D002251:Carbon Tetrachloride; D004878:Ergotamine